Technical Analysis for AVEO - AVEO Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.71 -5.33% -0.04
AVEO closed down 5.33 percent on Friday, May 17, 2019, on 26 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AVEO trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -5.33%
Expansion Pivot Sell Setup Bearish Swing Setup -5.33%
Lower Bollinger Band Walk Weakness -5.33%
Below Lower BB Weakness -5.33%
Lower Bollinger Band Touch Weakness -5.33%

Older signals for AVEO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its principal product candidate is tivozanib, for which the company has filed a new drug application with the U.S. food and drug administration as a proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). The company's product pipeline also comprises TAURUS, which is in a Phase II clinical study for the treatment of RCC. In addition, its product pipeline includes Biomarker Assessment of Tivozanib in ONcology program, such as BATON-RCC, a Phase II exploratory biomarker study in patients with advanced RCC; BATON-CRC, a Phase II clinical trial for the first-line therapy in patients with advanced metastatic colorectal cancer; and BATON-BC, a Phase II clinical trial for the treatment of patients with locally recurrent or metastatic triple negative breast cancer. Further, the company has a pipeline of monoclonal antibodies, including Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II clinical stage for the treatment of non-small cell lung cancer; and AV-203, a monoclonal antibody that targets the ErbB3 receptor and is in Phase I clinical trial for the treatment of solid tumors. AVEO Pharmaceuticals, Inc. has strategic partnerships with Merck & Co., Inc; OSI Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Astellas Pharma Inc.; and Biogen Idec, Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Cancer Food Drugs Chemical Compounds Solid Tumors Antibodies Monoclonal Antibodies Cancer Treatments Non Small Cell Lung Cancer Cancer Therapies Seattle Genetics Cancer Therapeutics Treatment Of Non Small Cell Lung Cancer Erb B3
Is AVEO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.59
52 Week Low 0.4906
Average Volume 7,778,957
200-Day Moving Average 1.7284
50-Day Moving Average 0.8583
20-Day Moving Average 0.8866
10-Day Moving Average 0.853
Average True Range 0.0792
ADX 26.55
+DI 21.9435
-DI 26.4188
Chandelier Exit (Long, 3 ATRs ) 0.8824
Chandelier Exit (Short, 3 ATRs ) 0.9376
Upper Bollinger Band 1.0222
Lower Bollinger Band 0.751
Percent B (%b) -0.15
BandWidth 30.588766
MACD Line -0.0394
MACD Signal Line -0.013
MACD Histogram -0.0264
Fundamentals Value
Market Cap 84 Million
Num Shares 118 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -1.15
Price-to-Sales 80.41
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.79
Resistance 3 (R3) 0.79 0.77 0.77
Resistance 2 (R2) 0.77 0.75 0.77 0.77
Resistance 1 (R1) 0.74 0.74 0.73 0.74 0.76
Pivot Point 0.72 0.72 0.72 0.72 0.72
Support 1 (S1) 0.69 0.70 0.68 0.69 0.66
Support 2 (S2) 0.67 0.69 0.67 0.65
Support 3 (S3) 0.64 0.67 0.65
Support 4 (S4) 0.64